Fig. 2: Modulation of interferon-γ (IFNG) gene expression following stimulation of pre- and post-vaccination blood samples with recombinant (r) EE2 or major capsid protein (MCP) vaccine antigens (Ag). | Nature Communications

Fig. 2: Modulation of interferon-γ (IFNG) gene expression following stimulation of pre- and post-vaccination blood samples with recombinant (r) EE2 or major capsid protein (MCP) vaccine antigens (Ag).

From: A safe, T cell-inducing heterologous vaccine against elephant endotheliotropic herpesvirus in a proof-of-concept study

Fig. 2

The longitudinal IFNG gene expression levels in samples stimulated with rEE2 or rMCP relative to the expression in time-matched phosphate buffered saline (PBS)-treated controls over the stage I (a, b) and stage II (c–f) study periods are shown for the three participating elephants (N = 3). Data are presented for each individual animal (stage I: n = 1; stage II: n = 2). Vertical dashed lines indicate time of vaccination with either rMVA-EE2-MCP virus vector (rMVA) or adjuvanted rEE2-rMCP-subunit (rAg) formulation. Horizontal dashed lines mark the highest IFNG expression level observed among baseline (pre-vaccination) samples. Through calculating the fold changes using the 2−(ΔΔCt) method, IFNG mRNA levels were normalised to those of the reference gene elongation factor−1α and PBS controls were set as 1. Asterisks below the trial week numbers indicate that a blood sample could not be obtained from an animal at this time point (elephant C: weeks 3 and 16) or samples that were excluded from further analysis due to unsatisfactory downstream quality checks (elephant B: weeks 13, 16 and 20). Source data are provided as a Source Data file.

Back to article page